StockData

Apyx Medical vs Lensar

APYX and LNSR side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How APYX and LNSR compare

Apyx Medical is the larger company, worth 2.2 times as much as Lensar ($126M against $56.3M).

Apyx Medical grew revenue faster over the last twelve months (24.4% versus 1.6% for Lensar).

Lensar keeps more of each dollar of sales as profit, with a net margin of 56.1% compared with −14.2% at Apyx Medical.

Lensar scores higher on the StockData Score (8 against 4 for Apyx Medical), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricAPYXLNSR
Size and price
Market cap$126M$56.3M
Share price$3.00$4.58
Change, 1 year−26.8%−55.0%
Change, 5 years−82.1%−35.5%
Beta (5Y)1.490.58
Employees205150
StockData Score
Total score48 (better)
Valuation score02 (better)
Growth score22
Performance score12 (better)
Health score12 (better)
Dividend score00
Valuation
P/S2.1×0.9× (better)
P/B13.1×5.1× (better)
FCF yield−7.0%–
Fair value$2.23$6.18
Margin of safety−34.6%25.9% (better)
Growth
Revenue growth (TTM)24.4% (better)1.6%
Revenue growth, 5Y average13.8%17.2% (better)
Profitability
Gross margin63.4% (better)52.0%
Operating margin−5.5%−3.3% (better)
Net margin−14.2%56.1% (better)
FCF margin−14.9%–
Return on equity−109%–
Return on invested capital−14.9%–
Financial health
Debt / equity3.690.17 (better)
Interest coverage−0.6×–
Current ratio4.95 (better)2.25
Altman Z-score0.91 (better)−0.93
Piotroski F-score5 (better)3
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions58.5%36.0%
Held by insiders6.8%–
Short interest, % of float0.62%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.